- Home
- ETV vs KROS Comparison
ETV vs KROS Comparison
Compare ETV & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- KROS
- Stock Information
- Founded
- ETV 2005
- KROS 2015
- Country
- ETV United States
- KROS United States
- Employees
- ETV N/A
- KROS N/A
- Industry
- ETV Investment Managers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ETV Finance
- KROS Health Care
- Exchange
- ETV Nasdaq
- KROS Nasdaq
- Market Cap
- ETV 1.6B
- KROS 1.8B
- IPO Year
- ETV N/A
- KROS 2020
- Fundamental
- Price
- ETV $14.15
- KROS $56.62
- Analyst Decision
- ETV
- KROS Strong Buy
- Analyst Count
- ETV 0
- KROS 8
- Target Price
- ETV N/A
- KROS $91.43
- AVG Volume (30 Days)
- ETV 252.5K
- KROS 383.1K
- Earning Date
- ETV 01-01-0001
- KROS 11-06-2024
- Dividend Yield
- ETV 8.75%
- KROS N/A
- EPS Growth
- ETV N/A
- KROS N/A
- EPS
- ETV N/A
- KROS N/A
- Revenue
- ETV N/A
- KROS $651,000.00
- Revenue This Year
- ETV N/A
- KROS $1,232.45
- Revenue Next Year
- ETV N/A
- KROS $126.39
- P/E Ratio
- ETV N/A
- KROS N/A
- Revenue Growth
- ETV N/A
- KROS 8037.50
- 52 Week Low
- ETV $11.05
- KROS $27.31
- 52 Week High
- ETV $13.50
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ETV 62.36
- KROS 38.94
- Support Level
- ETV $14.04
- KROS $65.54
- Resistance Level
- ETV $14.24
- KROS $70.26
- Average True Range (ATR)
- ETV 0.13
- KROS 3.17
- MACD
- ETV 0.02
- KROS -0.64
- Stochastic Oscillator
- ETV 84.92
- KROS 9.07
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.